ArticleFrontiers in microbiology2016
Dose Assessment of Cefquinome by Pharmacokinetic/Pharmacodynamic Modeling in Mouse Model of
Article in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Bovine Mastitis Therapy at a Crossroads: Pharmacokinetic Barriers, Biofilms, Antimicrobial Resistance, and Emerging Solutions.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Adaptive Resistance ofMicroorganisms · 2025Article
- From Herd Health to Public Health: Digital Tools for Combating Antibiotic Resistance in Dairy Farms.Antibiotics (Basel, Switzerland) · 2024Review
- Pharmacokinetics and pharmacodynamics of antibacterial peptide NZX in Staphylococcus aureus mastitis mouse model.Applied microbiology and biotechnology · 2024Article
- Pharmacokinetics and relative bioavailability study of two cefquinome sulfate intramammary infusions in cow milk.Frontiers in veterinary science · 2024Article
- A PK/PD model for the evaluation of clinical rifaximin dosage for the treatment of dairy cow mastitis induced by Escherichia coli.BMC veterinary research · 2023Article
- The pharmacokinetics and pharmacodynamics of cefquinome against Streptococcus agalactiae in a murine mastitis model.PloS one · 2023Article
- Pharmacokinetics and Pharmacodynamics of Fungal Defensin NZX AgainstFrontiers in microbiology · 2022Article
- Article
- Antibacterial pathway of cefquinome against Staphylococcus aureus based on label-free quantitative proteomics analysis.Journal of microbiology (Seoul, Korea) · 2021Article
- Kill Rate and Evaluation ofFrontiers in veterinary science · 2021Article
- PK/PD Modeling to Assess Rifaximin Clinical Dosage in a Mouse Model ofFrontiers in veterinary science · 2021Article
- Efficacy Prediction of Four Pharmaceutical Formulations for Intramammary Administration ContainingFrontiers in veterinary science · 2021Article
- Pharmacokinetics/Pharmacodynamics models of veterinary antimicrobial agents.Journal of veterinary science · 2019Review
- Efficacy of Cefquinome againstFrontiers in microbiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This work aimed to characterize the mammary gland pharmacokinetics of cefquinome after an intramammary administration and integrate pharmacokinetic/pharmacodynamic model. The pharmacokinetic profiles of cefquinome in gland tissue were measured using high performance liquid chromatograph. Therapeutic regimens covered various dosages ranging from 25 to 800 μg/gland and multiple dosing intervals of 8, 12, and 24 h. The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.